Osteomyelitis: Clinical Trials

4 trials for Osteomyelitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 4 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 34Completed 4
Phase 21Completed 1

Follow Osteomyelitis: new trials by email Literature Review of Osteomyelitis trials Research Report on Osteomyelitis

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections
sodium fusidate - Refractory Bone or Joint Infections
Phase 2 / Phase 3CompletedArrevus Inc.302015-12-012020-01-30
Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061)
Ertapenem sodium, Piperacillin/tazobactam sodium, Piperacillin/tazobactam-matching placebo - Infection; Diabetic Foot
Phase 3CompletedMerck Sharp & Dohme LLC5652011-09-022018-08-27
Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.
Tigecycline, Ertapenem - Bacterial Infections, Diabetic Foot
Phase 3CompletedWyeth is now a wholly owned subsidiary of Pfizer10612007-01-012010-04-28
Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis
trimethoprim-sulfamethoxazole, vancomycin - Osteomyelitis, Methicillin-resistant Staphylococcus Aureus
Phase 3CompletedUniversity of Washington22006-05-012023-04-11

Narrower conditions

Diabetes Complications (2)  ·  Diabetic Foot (2)  ·  Bacterial Infections (1)  ·  Cellulitis (1)  ·  Diabetes Mellitus (1)  ·  Foot Ulcer (1)  ·  Infections (1)  ·  Soft Tissue Infections (1)

Broader conditions

Bone Diseases (4)  ·  Bone Diseases, Infectious (4)  ·  Musculoskeletal Diseases (4)  ·  Infections (3)  ·  Cardiovascular Diseases (2)  ·  Diabetic Angiopathies (2)  ·  Diabetic Neuropathies (2)  ·  Endocrine System Diseases (2)  ·  Leg Ulcer (2)  ·  Skin Diseases (2)  ·  Skin Ulcer (2)  ·  Skin and Connective Tissue Diseases (2)  ·  Vascular Diseases (2)  ·  Bacterial Infections and Mycoses (1)  ·  Connective Tissue Diseases (1)

Interventions

Ertapenem (2)  ·  Amoxicillin (1)  ·  Fusidic Acid (1)  ·  L 749345 (1)  ·  Piperacillin (1)  ·  Piperacillin, Tazobactam Drug Combination (1)  ·  Tazobactam (1)  ·  Tigecycline (1)  ·  Trimethoprim, Sulfamethoxazole Drug Combination (1)  ·  Vancomycin (1)

Sponsors

Arrevus Inc. (1)  ·  Merck Sharp & Dohme LLC (1)  ·  University of Washington (1)  ·  Wyeth is now a wholly owned subsidiary of Pfizer (1)

Countries

United States (3)  ·  Argentina (1)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Canada (1)  ·  Chile (1)  ·  China (1)  ·  Colombia (1)  ·  Croatia (1)  ·  Denmark (1)  ·  Estonia (1)  ·  Finland (1)  ·  France (1)

Top investigators

Christian Ramers, MD (1)  ·  Jeanne Chan, PharmD, MPH (1)  ·  Jeanne M Marrazzo, MD, MPH (1)  ·  Lisa Taitsman, MD (1)  ·  M. Bradford Henley, MD (1)  ·  Matthew Golden, MD, MPH (1)  ·  Robert D Harrington, MD (1)  ·  Robert Dobbins, MD, PhD (1)  ·  Thomas R Hawn, MD, PhD (1)  ·  Timothy H. Dellitt, MD (1)

Results publications

PMID 24439136, PMID 26888908